At the largest hospital in Brooklyn, doctors are working to address disparities for patients facing advanced heart failure.

AngioDynamics announced today that it launched a new trial evaluating its AlphaVac F18 system in treating pulmonary embolism ...

The company’s RECOVER-AV trial is intended to further the adoption of its AlphaVac F1885 system in the European market.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vasc ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options ...

AngioDynamics, Inc. announced the launch of the RECOVER AV trial of the company’s AlphaVac F18⁸⁵ multipurpose mecha ...

Introduction Wearable cardioverter-defibrillators (WCD) have emerged as a valuable tool in the management of patients at risk ...

Cardiology Department Guglielmo Da Saliceto Hospital, Piacenza, Italy 2. Department of Clinical and Experimental Medicine, University of Parma, Italy Background Left ventricular myocardial crypts are ...

Boston Scientific (NYSE: BSX) received FDA approval to expand the indication for its current-generation Ingevity+ pacing ...

A Vascular Access Device (VAD) is a medical device designed to provide access to a patient’s bloodstream for various medical treatments, procedures, and interventions. It allows healthcare ...

CVKD READ THE FULL CVKD RESEARCH REPORT We are initiating coverage of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) with a $30.00 valuation. Cadrenal is a biopharmaceutical developing innovative therapies ...